Fair value measurements and investments (Tables)

6 Months Ended

Jun. 30, 2021

Fair Value Measurements And Investment Disclosure [Abstract]

Schedule of Financial Assets and Liabilities Recorded at Fair Value on Recurring Basis

The fair value measurements of the Company’s financial assets and liabilities measured on a recurring basis were as follows:

	June 30, 2021											December 31, 2020
(U.S. Dollars, in thousands)	Level 1		Level 2			Level 3			Total			Total
Assets
Neo Medical preferred equity securities	$	—	$	5,000		$	—		$	5,000		$	5,000
Neo Medical convertible loan agreement		—		—			6,500			6,500			7,160
Bone Biologics equity securities		—		—			—			—			—
Total	$	—	$	5,000		$	6,500		$	11,500		$	12,160
Liabilities
Spinal Kinetics contingent consideration	$	—	$	—		$	(20,700	)	$	(20,700	)	$	(35,400	)
Other contingent consideration		—		—			—			—			(375	)
Deferred compensation plan		—		(1,445	)		—			(1,445	)		(1,441	)
Total	$	—	$	(1,445	)	$	(20,700	)	$	(22,145	)	$	(37,216	)

Schedule of Reconciliation For Convertible Loan Measured At Fair Value Using Significant Unobservable Inputs

The following table provides a reconciliation of the beginning and ending balances of the Convertible Loan, measured at fair value using significant unobservable inputs (Level 3):

(U.S. Dollars, in thousands)	2021			2020
Fair value of Neo Medical Convertible Loan at January 1	$	7,160		$	—
Interest recognized in interest income, net		198			—
Foreign currency remeasurement recognized in other expense, net		(230	)		—
Unrealized loss recognized in other comprehensive income (loss)		(628	)		—
Fair value of Neo Medical Convertible Loan at June 30		6,500			—
Amortized cost basis of Neo Medical Convertible Loan at June 30		5,247			—

Schedule of Changes in Valuation of Securities

The following table provides quantitative information related to certain key assumptions utilized within the valuation as of June 30, 2021:

(U.S. Dollars, in thousands)	Fair Value as of June 30, 2021		Unobservable inputs	Estimate
Neo Medical Convertible Loan	$	6,500	Cost of equity discount rate		21.9	%
			Implied volatility		86.0	%

The following table provides a range of key assumptions used within the valuation as of June 30, 2021.

(U.S. Dollars, in thousands)	Fair Value as of June 30, 2021		Valuation Technique	Unobservable inputs	Range
Spinal Kinetics contingent consideration	$	20,700	Discounted cash flow	Revenue discount rate	7.0% - 7.2%
				Payment discount rate	3.1% - 3.2%
				Projected year of payment	2022

Schedule of Reconciliation For Contingent Consideration Measured At Fair Value Using Significant Unobservable Inputs

The following table provides a reconciliation of the beginning and ending balances for the Spinal Kinetics contingent consideration measured at estimated fair value using significant unobservable inputs (Level 3):

(U.S. Dollars, in thousands)	2021			2020
Spinal Kinetics contingent consideration estimated fair value at January 1	$	35,400		$	42,700
Increase (decrease) in fair value recognized in acquisition-related amortization and remeasurement		300			(6,900	)
Payment made		(15,000	)		—
Spinal Kinetics contingent consideration estimated fair value at June 30	$	20,700		$	35,800